Chemed Corp banner

Chemed Corp
F:CXM

Watchlist Manager
Chemed Corp Logo
Chemed Corp
F:CXM
Watchlist
Price: 390 EUR 1.04% Market Closed
Market Cap: €5.9B

Wall St Price Targets

CXM Price Targets Summary
Chemed Corp

Wall Street analysts forecast CXM stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CXM is 383.66 EUR with a low forecast of 340.33 EUR and a high forecast of 442.27 EUR.

Lowest Forecast
Price Target
340.33 EUR
13% Downside
Average Forecast
Price Target
383.66 EUR
2% Downside
Highest Forecast
Price Target
442.27 EUR
13% Upside
Chemed Corp Competitors:
Price Targets
BMRN
Biomarin Pharmaceutical Inc
54% Upside
DVA
DaVita Inc
-12% Downside
CNC
Concurrent Technologies PLC
14% Upside
COHU
Cohu Inc
-9% Downside
TNDM
Tandem Diabetes Care Inc
83% Upside

Revenue
Forecast

4% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
4% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 6%.

Gross Profit
Forecast

6% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 7%.

Operating Income
Forecast

6% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
6% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 13%.

Pre-Tax Income
Forecast

7% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
7% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 13%.

Net Income
Forecast

9% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
9% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CXM's stock price target?
Price Target
383.66 EUR

According to Wall Street analysts, the average 1-year price target for CXM is 383.66 EUR with a low forecast of 340.33 EUR and a high forecast of 442.27 EUR.

What is the Revenue forecast for Chemed Corp?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Chemed Corp?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 7%.

What is the Operating Income forecast for Chemed Corp?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 13%.

What is the Pre-Tax Income forecast for Chemed Corp?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 13%.

What is the Net Income forecast for Chemed Corp?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett